Business Context and Reporting Period
This Form 8-K filing by Vanda Pharmaceuticals Inc. (VNDA) reports on executive compensation decisions made by the Compensation Committee on February 16, 2024. The report covers the award of 2023 annual bonuses, the approval of 2024 base salaries and bonus targets, and the granting of restricted stock units (RSUs) to named executive officers.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation figures.
| Executive Officer | 2023 Bonus Awarded | 2024 Base Salary | 2024 Target Bonus % | RSU Shares Granted |
|---|---|---|---|---|
| Mihael Polymeropoulos, M.D. (CEO) | $983,112 | $933,000 | 80% | 450,000 |
| Kevin Moran (CFO) | $294,071 | $541,000 | 45% | 125,000 |
| Gunther Birznieks (SVP, BD) | $320,580 | $541,000 | 45% | 125,000 |
| Timothy Williams (SVP, GC) | $320,580 | $541,000 | 45% | 125,000 |
| Joakim Wijkstrom (SVP, CMO) | $252,000 | $560,000 | 45% | 32,700 |
Material Changes
The filing details the transition from 2023 performance-based bonuses to 2024 compensation structures. Notable changes include:
- CEO Compensation: The CEO received a 2023 bonus of $983,112. For 2024, the base salary is set at $933,000 with a target bonus of 80% of base salary.
- Executive Salary Standardization: Three senior vice presidents (CFO, Business Development, General Counsel) have been set to an identical 2024 base salary of $541,000.
- Equity Grants: RSUs were granted to all named officers, with the CEO receiving a significantly larger allocation (450,000 shares) compared to other officers (125,000 shares or less).
Guidance, Outlook, and Risks
Management Commentary: The Compensation Committee reviewed an analysis of executive compensation relative to a peer group conducted by Willis Towers Watson prior to making these decisions.
Equity Vesting: All RSU awards granted in this filing will vest in four equal annual installments beginning on March 1, 2025.
Risks and Contingencies: The filing does not disclose specific operational risks, contingencies, or unusual items beyond the standard disclosure of executive compensation.
Investor Verification Checklist
- Verify the total cash outflow for 2023 bonuses ($2.17 million total for named officers) against the company's current cash position.
- Confirm the impact of the 2024 salary increases and bonus targets on the company's projected operating expenses.
- Review the dilution impact of the 857,700 total RSU shares granted to named executive officers.
- Check the vesting schedule start date (March 1, 2025) to understand future equity expense recognition.